Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity ...Middle East

13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

Hence then, the article about viking therapeutics announces completion of enrollment in phase 2 venture oral dosing trial of vk2735 tablet formulation in patients with obesity was published today ( Wednesday 26/03/2025 - 02:07 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity )

Also on site :

• Ukraine will try “to get some concessions” from Trump at meeting
• Numbrix 9 - December 28
• Getting hired in 2026 is all about your ‘microcredentials’ says CEO of $1.3 billion learning platform—this is what he tells Gen Z to focus on